1. Academic Validation
  2. Development and validation of a turbulent flow chromatography and tandem mass spectrometry method for the quantitation of methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum

Development and validation of a turbulent flow chromatography and tandem mass spectrometry method for the quantitation of methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum

  • J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:169-75. doi: 10.1016/j.jchromb.2015.08.025.
Ryan C Schofield 1 Lakshmi V Ramanathan 1 Kazunori Murata 1 Marie Grace 2 Martin Fleisher 1 Melissa S Pessin 1 Dean C Carlow 3
Affiliations

Affiliations

  • 1 Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • 2 Department of Pathology and Laboratory Medicine, Mount Sinai School of Medicine, New York, NY, United States.
  • 3 Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Electronic address: carlowd@mskcc.org.
Abstract

A rapid and simple turbulent flow liquid chromatography (TFC-LC) method implementing positive heated electrospray ionization (HESI) for the accurate and precise determination of methotrexate (MTX), 7-hydroxy methotrexate (7-OH MTX), and 4-amino-4-deoxy-N(10)-methylpteroic acid (DAMPA) concentrations in serum was developed. MTX was isolated from serum samples (100μL) after protein precipitation with methanol containing formic acid and internal standard (MTX-D3) followed by centrifugation. The supernatant was injected into the turbulent flow liquid chromatography which is followed by electrospray positive ionization tandem mass spectrometry (TFC-LC-MS/MS) and quantified using a six-point calibration curve. For MTX and DAMPA the assays were linear from 10 to 1000nmol/L and for 7-OH MTX from 20 to 2000nmol/L. Dilutions of 10, 100 and 1000-fold were validated giving a clinically reportable range of 10nmol/L to 5×10(5)nmol/L. Within-day and between-day precisions at concentrations spanning the analytical measurement ranges were less than 10% for all three analytes. MTX, DAMPA and 7-OH MTX were sufficiently stable under all relevant analytical conditions. No significant matrix effect was observed during the method validation. The TFC-LC-MS/MS MTX method was also compared with three other clinically validated MTX assays: a dihydrofolate reductase (DHFR) inhibition assay, an immunoassay based on fluorescence polarization and a previously developed LC-MS/MS assay.

Keywords

7-Hydroxy methotrexate; Carboxypeptidase-G2; DAMPA; Dihydrofolate reductase inhibition assay; Fluorescence polarization immunoassay; Mass spectrometry; Method correlation; Methotrexate; Therapeutic drug monitoring; Turbulent flow liquid chromatography.

Figures